Spero Therapeutics announced its financial results for Q1 2026, reporting a net loss of $7.2 million, an improvement from $13.9 million loss in Q1 2025, driven by reduced R&D and administrative expenses. The company is awaiting an FDA decision on its oral antibiotic tebipenem HBr for complicated urinary tract infections, with a PDUFA date set for June 18, 2026. Tebipenem HBr, developed with GSK, showed promising Phase 3 trial results, potentially offering a new oral treatment alternative to IV antibiotics. Spero maintains its cash runway guidance into 2028 and is exploring opportunities to expand its clinical-stage portfolio.
The global ovarian cancer diagnostics market is projected to grow from $4.92 billion in 2025 to $8.08 billion by 2035, at a CAGR of 5.06%. Growth is fueled by rising ovarian cancer cases, increased adoption of AI-powered imaging, biomarker testing, a...
The FDA has approved Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for treating complicated urinary tract infections (cUTIs) in adults with limited oral treatment options. This approval is based on the PIVOT-PO phase III trial show...
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
Biotech companies are increasingly adopting a dual-track approach by preparing for IPOs while also engaging with potential acquirers, as investors have become more selective since the pandemic boom. Big Pharma is actively seeking to replenish drug pi...
